Literature DB >> 21321564

High risk of lifetime history of suicide attempts among CYP2D6 ultrarapid metabolizers with eating disorders.

E M Peñas-Lledó, P Dorado, Z Agüera, M Gratacós, X Estivill, F Fernández-Aranda, A Llerena.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21321564     DOI： 10.1038/mp.2011.5

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN： 1359-4184            Impact factor:   15.992


× No keyword cloud information.
  14 in total

Review 1.  CYP2D6 variation, behaviour and psychopathology: implications for pharmacogenomics-guided clinical trials.

Authors:  Eva M Peñas-Lledó; Adrián Llerena
Journal:  Br J Clin Pharmacol       Date:  2014-04       Impact factor: 4.335

2.  Impact of cytochrome P450 genes on suicide attempt and risk.

Authors:  Eva M Peñas-Lledó; M Eugenia G Naranjo; Adrián Llerena
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2013-03-16       Impact factor: 5.270

Review 3.  Pharmacogenetic research activity in Central America and the Caribbean: a systematic review.

Authors:  Carolina Céspedes-Garro; María-Eugenia G Naranjo; Fernanda Rodrigues-Soares; Adrián LLerena; Jorge Duconge; Lazara K Montané-Jaime; Hilda Roblejo; Humberto Fariñas; María de Los A Campos; Ronald Ramírez; Víctor Serrano; Carmen I Villagrán; Eva M Peñas-LLedó
Journal:  Pharmacogenomics       Date:  2016-09-16       Impact factor: 2.533

4.  High frequency of CYP2D6 ultrarapid metabolizers in Spain: controversy about their misclassification in worldwide population studies.

Authors:  M E G Naranjo; F de Andrés; A Delgado; J Cobaleda; E M Peñas-Lledó; A LLerena
Journal:  Pharmacogenomics J       Date:  2016-06-07       Impact factor: 3.550

5.  A combined high CYP2D6-CYP2C19 metabolic capacity is associated with the severity of suicide attempt as measured by objective circumstances.

Authors:  E Peñas-Lledó; S Guillaume; M E G Naranjo; A Delgado; I Jaussent; H Blasco-Fontecilla; P Courtet; A LLerena
Journal:  Pharmacogenomics J       Date:  2014-08-12       Impact factor: 3.550

6.  The association between CYP2D6 genotype and switching antipsychotic medication to clozapine.

Authors:  Jochem G Gregoor; Karen van der Weide; Jan van der Weide; Harold J G M van Megen; Antoine C G Egberts; Eibert R Heerdink
Journal:  Eur J Clin Pharmacol       Date:  2013-07-07       Impact factor: 2.953

7.  Integrating multi-omics biomarkers and postprandial metabolism to develop personalized treatment for anorexia nervosa.

Authors:  Pei-An Betty Shih
Journal:  Prostaglandins Other Lipid Mediat       Date:  2017-02-21       Impact factor: 3.072

8.  A one-year follow-up study of treatment-compliant suicide attempt survivors: relationship of CYP2D6-CYP2C19 and polypharmacy with suicide reattempts.

Authors:  Eva M Peñas-Lledó; Sebastien Guillaume; Fernando de Andrés; Ana Cortés-Martínez; Jonathan Dubois; Jean Pierre Kahn; Marion Leboyer; Emilie Olié; Adrián LLerena; Philippe Courtet
Journal:  Transl Psychiatry       Date:  2022-10-18       Impact factor: 7.989

9.  High frequency of CYP2D6 ultrarapid metabolizer genotypes in an Ashkenazi Jewish population from Argentina.

Authors:  G Moya; P Dorado; V Ferreiro; M E G Naranjo; E M Peñas-Lledó; A LLerena
Journal:  Pharmacogenomics J       Date:  2016-04-12       Impact factor: 3.550

10.  The impact of Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes on suicide attempt and suicide risk-a European multicentre study on treatment-resistant major depressive disorder.

Authors:  Peter Höfer; Alexandra Schosser; Raffaella Calati; Alessandro Serretti; Isabelle Massat; Neslihan Aygun Kocabas; Anastasios Konstantinidis; Sylvie Linotte; Julien Mendlewicz; Daniel Souery; Joseph Zohar; Alzbeta Juven-Wetzler; Stuart Montgomery; Siegfried Kasper
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-10-19       Impact factor: 5.270
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.